Semaglutide vs tirzepatide. Which GLP-1 for which patient?
Semaglutide vs tirzepatide — mechanism, trial weight-loss percentages, side-effect profiles, cost, and how we choose between them.
Tirzepatide (Mounjaro, Zepbound) produced greater average weight reduction than semaglutide (Ozempic, Wegovy) in trials — roughly 20 percent of body weight versus roughly 15 percent over a year-plus of full-dose therapy. Semaglutide carries the longer safety record. Both are weekly injections with overlapping GI side effects. The right molecule depends on your starting point, your tolerance, and your coverage — which is what the consultation is for.
Semaglutide vs tirzepatide, at a glance.
Trial figures are averages from the registration studies, not individual predictions. Cost figures are typical Los Angeles market ranges across branded and compounded programs, not our pricing.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP receptor agonist |
| Brand names | Ozempic (type 2 diabetes) · Wegovy (weight management) | Mounjaro (type 2 diabetes) · Zepbound (weight management) |
| Weight reduction in trials | ~15% of body weight (STEP-1, 68 weeks) | ~21% of body weight at the highest dose (SURMOUNT-1, 72 weeks) |
| Dosing cadence | Weekly subcutaneous injection · titrated every 4 weeks | Weekly subcutaneous injection · titrated every 4 weeks |
| FDA labels | T2D since 2017 (Ozempic) · chronic weight management since 2021 (Wegovy) | T2D since 2022 (Mounjaro) · chronic weight management since 2023 (Zepbound) |
| Side-effect profile | GI-led — nausea, constipation, early fullness; clusters at dose increases | GI-led — slightly more nausea and diarrhea, slightly less constipation in trials |
| Typical LA monthly cost | $300 – $1,000 per month depending on source and coverage | $350 – $1,200 per month depending on source and coverage |
One receptor or two.
Semaglutide — the molecule inside both Ozempic and Wegovy — is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, the gut hormone that signals satiety to the brain, slows gastric emptying, and prompts insulin release after meals. One molecule, one receptor, one well-mapped pathway with over a decade of post-market data behind it.
Tirzepatide — sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management — acts on that same GLP-1 pathway and on a second one: GIP, glucose-dependent insulinotropic polypeptide. GIP's effects in isolation are modest, but activated alongside GLP-1 the two pathways appear to produce a greater combined effect on appetite and adipose handling than either alone.
That second receptor is the likely reason tirzepatide outperformed semaglutide on average in trials — including SURMOUNT-5, the direct head-to-head, where tirzepatide produced roughly 50 percent greater average weight reduction. Averages aren't individuals. Some patients respond strongly to semaglutide and modestly to tirzepatide; physiology doesn't read the trial data.
How we choose, goal by goal.
There is no universally better molecule — there is a better molecule for a given patient. These are the axes the consultation actually turns on.
| Greatest average reductionHigher starting BMI · metabolic comorbidities | Tirzepatide, on the trial evidence. For patients with more weight to lose or significant metabolic disease, the greater average potency of the dual agonist is often the deciding factor. We still titrate to effect, not to label maximum. |
|---|---|
| Longest safety recordConservative patients · long-horizon planning | Semaglutide. Approved in 2017, with post-market surveillance data tirzepatide simply hasn't had time to accumulate. For patients who weigh track record heavily, semaglutide remains the conservative choice — and its results are substantial in their own right. |
| TolerabilityPrior GI intolerance | Patient-specific. The side-effect profiles overlap, but individuals often tolerate one molecule meaningfully better than the other. Prior intolerance to semaglutide is a reasonable indication to try tirzepatide, and vice versa — with a fresh titration, not a dose swap. |
| Cost and coverageInsurance realities | Coverage varies by plan, indication, and brand more than by molecule. Diabetes-label coverage (Ozempic, Mounjaro) is typically broader than weight-management coverage (Wegovy, Zepbound). We work through what's actually available to you rather than prescribing around insurance. |
If you're really comparing brands, not molecules.
Patients often arrive asking about Ozempic versus Mounjaro, or Wegovy versus Zepbound — which is really this molecule comparison wearing brand names. But two adjacent questions deserve their own answers: Wegovy versus Ozempic is a same-molecule comparison (both semaglutide, different FDA labels), and Mounjaro versus Zepbound is the same situation for tirzepatide. We keep a dedicated guide for each because the label differences drive real consequences for dose ceilings and insurance.
Switching between molecules mid-program is common and unremarkable. It isn't a 1:1 conversion — we restart titration from a low dose and climb to a new equivalent — but a patient who plateaus on semaglutide or tolerates tirzepatide poorly isn't stuck. The program is supervised precisely so these decisions get made on evidence, visit by visit.
Plainly"The trial averages favor tirzepatide. The safety record favors semaglutide. The right answer favors neither until we've seen your history, your labs, and your coverage."
Supervised by Dr. Charles Peterson, board-certified physician with nearly a decade in aesthetic medicine.
Questions we get.
Is tirzepatide just a stronger semaglutide?
No — it's a different molecule with a second mechanism. Tirzepatide activates both GLP-1 and GIP receptors, where semaglutide activates GLP-1 alone. The dual action likely explains the greater average weight reduction in trials, but the molecules aren't interchangeable doses of the same thing.
Which has worse side effects?
They're broadly similar — both are GI-led, clustering in the weeks after each dose increase. In trials, tirzepatide showed slightly more nausea and diarrhea; semaglutide slightly more constipation. Individual tolerance varies more than the trial averages suggest, and slower titration helps with both.
Do both require the same screening?
Essentially, yes. The contraindication list is shared across the class — medullary thyroid carcinoma history, MEN-2, prior pancreatitis, pregnancy. Intake, baseline labs, and monthly monitoring during titration are identical regardless of which molecule we choose.
Can I switch from semaglutide to tirzepatide?
Yes, with a fresh titration. There's no 1:1 dose conversion — we restart at tirzepatide's entry dose and climb every four weeks. Plateaued response or persistent intolerance on one molecule are both reasonable indications to switch. The reverse switch works the same way.
Which costs less?
Semaglutide, modestly. LA market ranges run roughly $300 to $1,000 per month for semaglutide programs and $350 to $1,200 for tirzepatide, depending heavily on branded versus compounded source and insurance. Our program pricing is discussed at consultation.
Continue.
GLP-1 mechanism, on-label vs off-label use, candidacy, side-effect management, what happens when you stop.
Wegovy vs Ozempic — both are semaglutide. The FDA-label split, dose ceilings, insurance implications, and which fits weight management.
Mounjaro vs Zepbound — both are tirzepatide. The diabetes vs chronic-weight-management label split and what it means for access and cost.
Dosing schedule, week-by-week expectations, side-effect timeline, food strategies during titration, the Wegovy vs Ozempic distinction.